Autolus Therapeutics Announces License of AUCATZYL (Obecabtagene Autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 Years) With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
William Blair Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics: Promising Developments in Lupus Nephritis Drive Buy Rating
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Catalyst Watch: Spotlight on Tesla, Alphabet Earnings, AACR Drug Data, and Global PMI Reports
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Autolus Therapeutics Price Target Maintained With a $10.00/Share by Needham
12 Health Care Stocks Moving In Wednesday's After-Market Session
Autolus Therapeutics Announces Leadership Transition in Finance
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
Need To Know: Analysts Are Much More Bullish On Autolus Therapeutics Plc (NASDAQ:AUTL) Revenues
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $10
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Autolus Therapeutics, Lowers Price Target to $6